Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials.

Lupus Sci Med · 2026 · PMC13064137 · PMID 41951251

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

At week 52 of the TULIP-1/TULIP-2 treatment period, a higher proportion of patients attained DORIS remission with anifrolumab versus placebo regardless of IS history; the improved rates of DORIS remission with anifrolumab were nominally significant in both IS-inexperienced and IS-experienced patients.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.